Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

Trial Profile

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 23 Sep 2019 According to an ACADIA Pharmaceuticals media release, Primary endpoint (Change from Baseline to Week 8 in the Hamilton Depression Scale -17 items (HAMD-17) total score) has been met.
    • 23 Sep 2019 Results presented in an ACADIA Pharmaceuticals Media Release.
    • 23 Sep 2019 According to an ACADIA Pharmaceuticals media release, results were presented at he 2019 International Congress of Parkinsons Disease and Movement Disorders (MDS) in Nice, France.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top